Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Use of Rituximab and Risk of Re-hospitalization for Children with Neuromyelitis Optica Spectrum Disorder.

Gmuca S, Xiao R, Weiss PF, Waldman AT, Gerber JS.

Mult Scler Demyelinating Disord. 2018 Apr;3. pii: 3. doi: 10.1186/s40893-018-0035-9. Epub 2018 Apr 17.

2.

Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up.

Evangelopoulos ME, Andreadou E, Koutsis G, Koutoulidis V, Anagnostouli M, Katsika P, Evangelopoulos DS, Evdokimidis I, Kilidireas C.

J Neurol Sci. 2017 Jan 15;372:92-96. doi: 10.1016/j.jns.2016.11.016. Epub 2016 Nov 10.

PMID:
28017256
3.

Disease course, progression and activity of neuromyelitis optica (NMOSD) in patients who were treated with Rituximab, 6 and 12 months after receiving the first dose of drug, in Isfahan city.

Ashtari F, Mehdipour R, Shaygannejad V, Mansourian M.

Mult Scler Relat Disord. 2019 Jun 20;34:77-82. doi: 10.1016/j.msard.2019.06.013. [Epub ahead of print]

PMID:
31233958
4.

Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica: Influence of FCGR3A Polymorphisms on the Therapeutic Response to Rituximab.

Kim SH, Jeong IH, Hyun JW, Joung A, Jo HJ, Hwang SH, Yun S, Joo J, Kim HJ.

JAMA Neurol. 2015 Sep;72(9):989-95. doi: 10.1001/jamaneurol.2015.1276.

PMID:
26167726
5.

Clinical evaluation of rituximab treatment for neuromyelitis optica.

Fernández-Megía MJ, Casanova-Estruch B, Pérez-Miralles F, Ruiz-Ramos J, Alcalá-Vicente C, Poveda-Andrés JL.

Neurologia. 2015 Oct;30(8):461-4. doi: 10.1016/j.nrl.2014.09.001. Epub 2014 Nov 11. English, Spanish.

6.

Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients.

Radaelli M, Moiola L, Sangalli F, Esposito F, Barcella V, Ferrè L, Rodegher M, Colombo B, Fazio R, Martinelli V, Comi G.

Mult Scler. 2016 Apr;22(4):511-9. doi: 10.1177/1352458515594042. Epub 2015 Jul 21.

PMID:
26199350
7.

Rituximab in Neuromyelitis Optica Spectrum Disorders: Our Experience.

Jade JD, Bansi S, Singhal B.

Ann Indian Acad Neurol. 2017 Jul-Sep;20(3):229-232. doi: 10.4103/aian.AIAN_499_16.

8.

A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder.

Kim SH, Huh SY, Lee SJ, Joung A, Kim HJ.

JAMA Neurol. 2013 Sep 1;70(9):1110-7.

PMID:
23897062
9.

Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder.

Nosadini M, Alper G, Riney CJ, Benson LA, Mohammad SS, Ramanathan S, Nolan M, Appleton R, Leventer RJ, Deiva K, Brilot F, Gorman MP, Waldman AT, Banwell B, Dale RC.

Neurol Neuroimmunol Neuroinflamm. 2016 Jan 21;3(1):e188. doi: 10.1212/NXI.0000000000000188. eCollection 2016 Feb.

10.

Clinical characteristics and long-term visual outcome of optic neuritis in neuromyelitis optica spectrum disorder: A comparison between Thai and American-Caucasian cohorts.

Vanikieti K, Poonyathalang A, Jindahra P, Bouzika P, Rizzo JF 3rd, Cestari DM.

Mult Scler Relat Disord. 2017 Oct;17:87-91. doi: 10.1016/j.msard.2017.07.013. Epub 2017 Jul 10.

PMID:
29055481
11.

Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability.

Zéphir H, Bernard-Valnet R, Lebrun C, Outteryck O, Audoin B, Bourre B, Pittion S, Wiertlewski S, Ouallet JC, Neau JP, Ciron J, Clavelou P, Marignier R, Brassat D.

J Neurol. 2015 Oct;262(10):2329-35. doi: 10.1007/s00415-015-7852-y. Epub 2015 Jul 21.

PMID:
26194198
12.

Rituximab use in pediatric central demyelinating disease.

Beres SJ, Graves J, Waubant E.

Pediatr Neurol. 2014 Jul;51(1):114-8. doi: 10.1016/j.pediatrneurol.2014.02.007. Epub 2014 Feb 15.

PMID:
24768216
13.

Analysis of the treatment of neuromyelitis optica.

Torres J, Pruitt A, Balcer L, Galetta S, Markowitz C, Dahodwala N.

J Neurol Sci. 2015 Apr 15;351(1-2):31-35. doi: 10.1016/j.jns.2015.02.012. Epub 2015 Feb 13.

PMID:
25727350
14.

Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints.

Jeong IH, Park B, Kim SH, Hyun JW, Joo J, Kim HJ.

Mult Scler. 2016 Mar;22(3):329-39. doi: 10.1177/1352458515587752. Epub 2015 Jun 3.

PMID:
26041804
15.

Rituximab reduces attacks in Chinese patients with neuromyelitis optica spectrum disorders.

Ip VH, Lau AY, Au LW, Fan FS, Chan AY, Mok VC, Wong KS.

J Neurol Sci. 2013 Jan 15;324(1-2):38-9. doi: 10.1016/j.jns.2012.09.024. Epub 2012 Oct 2.

PMID:
23040959
16.

The Efficacy and Tolerability of Mycophenolate Mofetil in Treating Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder in Western China.

Chen H, Zhang Y, Shi Z, Feng H, Yao S, Xie J, Zhou H.

Clin Neuropharmacol. 2016 Mar-Apr;39(2):81-7. doi: 10.1097/WNF.0000000000000131.

PMID:
26818042
17.

Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID).

Rommer PS, Dörner T, Freivogel K, Haas J, Kieseier BC, Kümpfel T, Paul F, Proft F, Schulze-Koops H, Schmidt E, Wiendl H, Ziemann U, Zettl UK; GRAID investigators.

J Neuroimmune Pharmacol. 2016 Mar;11(1):1-8. doi: 10.1007/s11481-015-9646-5. Epub 2015 Nov 20.

PMID:
26589235
18.

Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success.

Greenberg BM, Graves D, Remington G, Hardeman P, Mann M, Karandikar N, Stuve O, Monson N, Frohman E.

Mult Scler. 2012 Jul;18(7):1022-6. doi: 10.1177/1352458511432896. Epub 2012 Jan 19.

PMID:
22261118
19.

An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica.

Collongues N, de Seze J.

Ther Adv Neurol Disord. 2016 May;9(3):180-8. doi: 10.1177/1756285616632653. Epub 2016 Mar 23. Review.

20.

Effects of rituximab on lymphocytes in multiple sclerosis and neuromyelitis optica.

Graves J, Vinayagasundaram U, Mowry EM, Matthews IR, Marino JA, Cheng J, Waubant E.

Mult Scler Relat Disord. 2014 Mar;3(2):244-52. doi: 10.1016/j.msard.2013.10.003. Epub 2013 Oct 25.

PMID:
25878012

Supplemental Content

Support Center